{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:23:15Z","timestamp":1783117395449,"version":"3.54.6"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pre\u2010exposure prophylaxis (PrEP) represents a major advance in HIV prevention, but its rollout in France remains limited, particularly among women, migrants and socially vulnerable populations. Despite full reimbursement by the national health system, oral PrEP is still rarely prescribed outside hospital settings, hindered by organizational constraints, inaccurate medical perceptions and persistent access inequalities. In this paper, we discuss the current limits of PrEP implementation in France, identify structural and individual barriers to its uptake and highlight possible strategies to make HIV prevention more accessible for all vulnerable populations across the country.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The goal of eliminating HIV transmission by 2030 in France continues to be jeopardized by insufficient PrEP coverage. The current prevention model remains overly hospital\u2010centred and primarily focused on a group of men who have sex with men (MSM), which limits its broader impact. In addition to structural barriers, the insufficient diversity of prescribers and the lack of inclusive communication continue to reinforce inequalities in access. The arrival of long\u2010acting injectable PrEP offers an important opportunity to ensure greater discretion and better adherence. However, its success will depend on expanding the range of authorized prescribers to include gynaecologists, general practitioners and family planning clinics, supported by specific training and outreach consultations. Equally critical is strengthening public awareness campaigns and extending them beyond MSM and urban centres such as Paris, to reach diverse populations across the country. Durable improvements in PrEP uptake and retention also depend on close collaboration with community\u2010based organizations, building trust with marginalized populations and participatory approaches that actively listen to individuals\u2019 concerns and lived experiences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>France, which is lagging behind its objective of ending the HIV epidemic, has the opportunity to rethink its prevention strategy to address unmet needs and move beyond a hospital\u2010 and MSM\u2010centred model. A structural, coordinated and inclusive response is essential to expand PrEP uptake and ensure equitable protection for all populations at risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jia2.70118","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:41:18Z","timestamp":1777448478000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Towards More Accessible and More Inclusive PrEP to Break the Cycle of HIV in France"],"prefix":"10.1002","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"first","affiliation":[{"name":"AP\u2010HP Nord, H\u00f4pital Bichat \u2010 Claude Bernard, Department of Infectious Diseases  Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1137 IAME  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Laure","family":"Chaix","sequence":"additional","affiliation":[{"name":"Department of Virology H\u00f4pital Saint\u2010Louis, AP\u2010HP  Paris France"},{"name":"CNR VIH, Sant\u00e9 Publique France, INSERM UMR 1342 Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"A.Kunkel F.Cazein andF.Lot Estimation de l'incidence du VIH et d'autres indicateurs cl\u00e9s 2024. [Accessed September 12 2025] https:\/\/www.santepubliquefrance.fr\/import\/estimation\u2010de\u2010l\u2010incidence\u2010du\u2010vih\u2010et\u2010d\u2010autres\u2010indicateurs\u2010cles."},{"key":"e_1_2_9_3_1","first-page":"542","article-title":"Prophylaxie Pr\u00e9\u2010exposition (PrEP) de l'infection au VIH Parmi les Hommes Ayant Des Rapports Sexuels avec des Hommes R\u00e9pondant \u00e0 l'enqu\u00eate Rapport au Sexe 2023: Qui Sont les \u00c9ligibles? Qui Sont les Usagers?","author":"Velter A.","year":"2023","journal-title":"Bulletin Epid\u00e9miologique Hebdomadaire"},{"key":"e_1_2_9_4_1","unstructured":"Sant\u00e9 Publique France Bulletin de sant\u00e9 publique infection \u00e0 VIH Mars 2019. 2019. [Accessed September 12 2025] https:\/\/www.santepubliquefrance.fr\/maladies\u2010et\u2010traumatismes\/infections\u2010sexuellement\u2010transmissibles\/vih\u2010sida\/documents\/bulletin\u2010national\/bulletin\u2010de\u2010sante\u2010publique\u2010infection\u2010a\u2010vih.\u2010mars\u20102019."},{"key":"e_1_2_9_5_1","unstructured":"S.Billioti de Gage D.Desplas andR.Dray\u2010Spira Suivi de l'utilisation de Truvada\u00ae ou g\u00e9n\u00e9riques pour une prophylaxie pr\u00e9\u2010exposition (PrEP) au VIH \u00e0 partir des donn\u00e9es du Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS): Actualisation des donn\u00e9es jusqu'au 30 Juin 2025 2025. [Accessed September 12 2025] https:\/\/www.assurance\u2010maladie.ameli.fr\/sites\/default\/files\/2025\u201011_suivi\u2010utilisation\u2010truvada\u2010ou\u2010generiques\u2010prophylaxie\u2010pre\u2010exposition\u2010vih_donnes\u2010actualisees\u2010juin\u20102025_assurance\u2010maladie.pdf."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002168"},{"key":"e_1_2_9_7_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS) Initiation d'un premier traitement antir\u00e9troviral chez l'adulte vivant avec le VIH 2024 [Accessed September 12 2025] https:\/\/www.has\u2010sante.fr\/upload\/docs\/application\/pdf\/2024\u201010\/initiation_dun_premier_traitement_antiretroviral_chez_ladulte_vivant_avec_le_vih_\u2010_fiche_pratique.pdf."},{"key":"e_1_2_9_8_1","unstructured":"Sant\u00e9 Publique France VIH et IST bact\u00e9riennes en France. Bilan 2023. 2024. [Accessed September 12 2025] https:\/\/www.santepubliquefrance.fr\/maladies\u2010et\u2010traumatismes\/infections\u2010sexuellement\u2010transmissibles\/vih\u2010sida\/documents\/bulletin\u2010national\/vih\u2010et\u2010ist\u2010bacteriennes\u2010en\u2010france.\u2010bilan\u20102023."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003074"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro794"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0339-4"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3915-5"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13367"},{"key":"e_1_2_9_14_1","unstructured":"S.Billioti de Gage T.Le Tri andR.Dray\u2010Spira Suivi de l'utilisation de Truvada\u00ae ou g\u00e9n\u00e9riques pour une prophylaxie pr\u00e9\u2010exposition (PrEP) au VIH \u00e0 partir des donn\u00e9es du Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS)2019. [Accessed September 12 2025] https:\/\/www.epi\u2010phare.fr\/app\/uploads\/2020\/04\/Billioti\u2010de\u2010Gage\u2010et\u2010al.\u20102019\u2010Suivi\u2010de\u2010l\u2010%E2%80%99utilisation\u2010de\u2010Truvada%C2%AE\u2010ou\u2010ge%CC%81ne%CC%81riques\u2010p.pdf."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278016"},{"key":"e_1_2_9_16_1","unstructured":"S.Billioti de Gage D.Desplas andR.Dray\u2010Spira Suivi de l'utilisation de Truvada\u00ae ou g\u00e9n\u00e9riques pour une prophylaxie pr\u00e9\u2010exposition (PrEP) au VIH \u00e0 partir des donn\u00e9es du Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS). 2024. [Accessed September 12 2025] https:\/\/www.epi\u2010phare.fr\/rapports\u2010detudes\u2010et\u2010publications\/prep\u2010vih\u20102024\/ [Accessed September 12 2025]."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(25)00062-3"},{"issue":"11","key":"e_1_2_9_18_1","article-title":"High Proportion of Post\u2010Migration HIV Acquisition in Migrant Men Who Have Sex With Men Receiving HIV Care in the Paris Region, and Associations With Social Disadvantage and Sexual Behaviours: Results of the ANRS\u2010MIE GANYMEDE Study, France, 2021 to 2022","volume":"29","author":"Palich R.","year":"2024","journal-title":"Euro Surveillance"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(25)00067-2"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(17)30211-6"},{"issue":"46","key":"e_1_2_9_21_1","first-page":"10","article-title":"Sub\u2010Saharan African Migrants Living With HIV Acquired After Migration, France, ANRS PARCOURS Study, 2012 to 2013","volume":"20","author":"Desgr\u00e9es\u2010du\u2010Lo\u00fb A.","year":"2015","journal-title":"Euro Surveillance"},{"key":"e_1_2_9_22_1","first-page":"542","article-title":"Part des Contaminations Apr\u00e8s l'arriv\u00e9e En france Parmi Les Personnes N\u00e9es \u00c0 L'\u00e9tranger D\u00e9couvrant Leur Infection \u00e0 VIH, France, 2012\u20132022","volume":"23","year":"2024","journal-title":"Bulletin Epid\u00e9miologique Hebdomadaire"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2023.02.010"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(22)00106-2"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae569"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae133"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-03023-9"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003174"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.16984"},{"key":"e_1_2_9_30_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS) Traitement pr\u00e9ventif pr\u00e9exposition de l'infection par le VIH 2025 [Accessed September 12 2025] https:\/\/www.has\u2010sante.fr\/upload\/docs\/application\/pdf\/2024\u201008\/traitement_preventif_pre\u2010exposition_de_linfection_par_le_vih_\u2010_fiche_synthetique_2024\u201008\u201006_11\u201005\u201011_184.pdf."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00235-2"},{"issue":"1","key":"e_1_2_9_36_1","article-title":"508. Cabotegravir Long\u2010Acting for Pre\u2010Exposure Prophylaxis (PrEP): Real World Data on On\u2010Time Dosing, HIV Testing and HIV Acquisition From the OPERA Cohort","volume":"12","author":"Mills A. M.","year":"2025","journal-title":"Open Forum Infectious Diseases"},{"key":"e_1_2_9_37_1","unstructured":"B. Bushby D. Murphy V. J. Cornelisse E. J. Wright A. E. Grulich and B. Bavinton Long\u2010Acting Injectable PrEP: A Scoping Review 2022. [Accessed September 12 2025] http:\/\/hdl.handle.net\/1959.4\/unsworks_81657."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-30474-8"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2024-056445"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.19.7.21103"},{"key":"e_1_2_9_41_1","unstructured":"AIDES La PrEP un Geste Simple Contre le Virus Du Sida\u2014AIDES Relance Sa Campagne sur le Traitement Pr\u00e9ventif Contre le VIH En Ciblant Deux Publics Particuli\u00e8rement \u00c9loign\u00e9s de la Pr\u00e9vention 2023. [Accessed September 12 2025] https:\/\/www.aides.org\/sites\/default\/files\/Aides\/bloc_telechargement\/CP_AIDES_PrEP_2023_VD.pdf."},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2025.2584600"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70075"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2025.06.007"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1586736"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70118","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.70118","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:07:13Z","timestamp":1783116433000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.70118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/jia2.70118"],"URL":"https:\/\/doi.org\/10.1002\/jia2.70118","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70118"}}